Are ARBs or ACE inhibitors preferred for nephropathy in diabetes?

MOspace/Manakin Repository

Breadcrumbs Navigation

Are ARBs or ACE inhibitors preferred for nephropathy in diabetes?

Please use this identifier to cite or link to this item: http://hdl.handle.net/10355/3014

[+] show full item record


Title: Are ARBs or ACE inhibitors preferred for nephropathy in diabetes?
Author: Foreman, Brett H.; Chambliss, M. Lee
Keywords: renal disease
mortality
anti-hypertensive therapy
type 2 diabetes
Date: 2004-03
Publisher: Family Physicians Inquiries Network
Citation: Journal of Family Practice, 53(3) 2004: 241-242.
Abstract: Angiotensin receptor blockers (ARBs) have been shown to reduce the progression of nephropathy in several consistent studies. While ACE inhibitors have not been as well studied for the endpoint of nephropathy, patients with nephropathy exhibit reduced mortality when treated with an ACE inhibitor (strength of recommendation: A, based on randomized controlled trials).
URI: http://hdl.handle.net/10355/3014

This item appears in the following Collection(s)

[+] show full item record